☰

Weihe Zhang, Ph.D. - Publications

Affiliations: 
2010 Department of Chemistry and Biochemistry Ohio University, Athens, OH, United States 
Area:
Organic Chemistry, Biochemistry
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Zheng H, Zhao J, Li B, Zhang W, Stashko MA, Minson KA, Huey MG, Zhou Y, Earp HS, Kireev D, Graham DK, DeRyckere D, Frye SV, Wang X. UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry. 220: 113534. PMID 34038857 DOI: 10.1016/j.ejmech.2021.113534  0.324
2020 Roberts DA, Wang L, Zhang W, Liu Y, Shriwas P, Qian Y, Chen X, Bergmeier SC. Isosteres of ester derived glucose uptake inhibitors. Bioorganic & Medicinal Chemistry Letters. 30: 127406. PMID 32736210 DOI: 10.1016/J.Bmcl.2020.127406  0.656
2019 Wong JP, Stuhlmiller TJ, Giffin LC, Lin C, Bigi R, Zhao J, Zhang W, Bravo Cruz AG, Park SI, Earp HS, Dittmer DP, Frye SV, Wang X, Johnson GL, Damania B. Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31346082 DOI: 10.1073/Pnas.1903991116  0.374
2018 Zhao J, Zhang D, Zhang W, Stashko MA, DeRyckere D, Vasileiadi E, Parker RE, Hunter D, Liu Q, Zhang Y, Norris-Drouin JL, Li B, Drewry D, Kireev DB, Graham DK, et al. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry. PMID 30347155 DOI: 10.1021/Acs.Jmedchem.8B01229  0.436
2016 McIver A, Zhang W, Liu Q, Jiang X, Stashko M, Nichols J, Miley M, Norris-Drouin J, Machius M, DeRyckere D, Wood E, Graham D, Earp HS, Kireev D, Frye S, et al. Discovery of Macrocyclic Pyrimidines as MerTK-specific Inhibitors. Chemmedchem. PMID 28032464 DOI: 10.1002/Cmdc.201600589  0.408
2016 Wang X, Liu J, Zhang W, Stashko MA, Nichols J, Miley MJ, Norris-Drouin J, Chen Z, Machius M, DeRyckere D, Wood E, Graham DK, Earp HS, Kireev D, Frye SV. Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. Acs Medicinal Chemistry Letters. 7: 1044-1049. PMID 27994735 DOI: 10.1021/Acsmedchemlett.6B00221  0.432
2016 DeRyckere D, Lee Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GD, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a MerTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27649555 DOI: 10.1158/1078-0432.Ccr-16-1330  0.374
2016 Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. Jci Insight. 1: e85630. PMID 27158668 DOI: 10.1172/Jci.Insight.85630  0.401
2015 Cummings CT, Zhang W, Davies KD, Kirkpatrick GD, Zhang D, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. Small molecule inhibition of MERTK is efficacious in non-small cell lung cancer models independent of driver oncogene status. Molecular Cancer Therapeutics. PMID 26162689 DOI: 10.1158/1535-7163.Mct-15-0116  0.463
2015 Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, et al. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 6: 6722-36. PMID 25762638 DOI: 10.18632/Oncotarget.3156  0.445
2014 Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. Journal of Medicinal Chemistry. 57: 7031-41. PMID 25068800 DOI: 10.1021/Jm500749D  0.405
2014 Graham DK, DeRyckere D, Lee-Sherick A, Hill AA, Minson K, Xiaodong W, Zhang W, Liu J, Frye S, Earp HS. Abstract A37: MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A37  0.442
2014 Earp HS, Darr D, Zimmermann A, Clark K, Sharpless NE, Bergmeier W, Zhang W, Wang X, DeRyckere D, Frye S, Graham D. Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma Cancer Research. 74: 947-947. DOI: 10.1158/1538-7445.Am2014-947  0.465
2014 Teodorovic LS, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Eckhardt SG, Earp HS, Graham DK. Abstract 730: Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant melanoma cell lines Cancer Research. 74: 730-730. DOI: 10.1158/1538-7445.Am2014-730  0.412
2014 Jacobsen KM, DeRyckere D, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. Abstract 3637: Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer Cancer Research. 74: 3637-3637. DOI: 10.1158/1538-7445.Am2014-3637  0.365
2014 Cummings CT, Davies KD, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Graham DK. Abstract 1742: Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer Cancer Research. 74: 1742-1742. DOI: 10.1158/1538-7445.Am2014-1742  0.495
2014 DeRyckere DA, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, Graham DK. Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia Cancer Research. 74: 1740-1740. DOI: 10.1158/1538-7445.Am2014-1740  0.475
2014 Newton TP, Cummings CT, Kirkpatrick GD, Hinz TK, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Heasley L, Graham DK. Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition Cancer Research. 74: 1736-1736. DOI: 10.1158/1538-7445.Am2014-1736  0.491
2014 Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, et al. Correction to Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors Journal of Medicinal Chemistry. 57: 7141-7141. DOI: 10.1021/Jm501216S  0.307
2014 Graham D, DeRyckere D, Wang X, Hill A, Zhang W, Frye S, Earp H. 352 UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemia European Journal of Cancer. 50: 114. DOI: 10.1016/S0959-8049(14)70478-2  0.385
2013 Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, et al. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry. 56: 9693-700. PMID 24219778 DOI: 10.1021/Jm501217P  0.426
2013 Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, et al. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry. 56: 9683-92. PMID 24195762 DOI: 10.1021/Jm401387J  0.487
2013 Liu J, Zhang W, Stashko MA, Deryckere D, Cummings CT, Hunter D, Yang C, Jayakody CN, Cheng N, Simpson C, Norris-Drouin J, Sather S, Kireev D, Janzen WP, Earp HS, et al. UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry. 65: 83-93. PMID 23693152 DOI: 10.1016/J.Ejmech.2013.03.035  0.499
2013 Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, ... ... Zhang W, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation. 123: 2257-67. PMID 23585477 DOI: 10.1172/Jci67816  0.452
2013 Zhang W, Liu J, Stashko MA, Wang X. Efficient solution-phase synthesis of 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines. Acs Combinatorial Science. 15: 10-9. PMID 23181516 DOI: 10.1021/Co300106F  0.302
2013 Acevedo G, Branchford BR, Law L, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Earp HS, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Mediate Synergistic Inhibition Of Platelet Aggregation In Combination With ADP/P2Y Antagonists Blood. 122: 3507-3507. DOI: 10.1182/Blood.V122.21.3507.3507  0.36
2013 DeRyckere D, Wang X, Hill AA, Zhang W, Stashko MA, Sather S, Cummings CE, Janzen WP, Frye SV, Earp HS, Graham DK. Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia Blood. 122: 2666-2666. DOI: 10.1182/Blood.V122.21.2666.2666  0.432
2013 Acevedo G, Branchford BR, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Liu J, Earp HS, Wang X, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Inhibit Platelet Aggregation In Vitro and Protect Mice From Arterial and Venous Thrombosis In Vivo Blood. 122: 2296-2296. DOI: 10.1182/Blood.V122.21.2296.2296  0.343
2013 Christoph S, Maag S, DeRyckere D, Graham DK, Frye SV, Earp HS, Liu J, Yang C, Zhang W, Wang X, Elmaagacli AH, Beelen D. Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma Blood. 122: 1957-1957. DOI: 10.1182/Blood.V122.21.1957.1957  0.417
2013 Schlegel J, Sambade M, Sather S, Moschos S, Tan A, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt G, Kuan P, Hamilton RL, Duncan LM, Miller CR, ... ... Zhang W, et al. Abstract 3037: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma. Cancer Research. 73: 3037-3037. DOI: 10.1158/1538-7445.Am2013-3037  0.428
2012 Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo Molecular Cancer Therapeutics. 11: 1672-1682. PMID 22689530 DOI: 10.1158/1535-7163.Mct-12-0131  0.693
2012 Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X. Abstract 3231: A small molecule inhibitor of glucose transporter 1 (Glut1) down-regulates glycolysis, induces cell cycle arrest, and inhibits cancer cell growthin vitroandin vivo Cancer Research. 72: 3231-3231. DOI: 10.1158/1538-7445.Am2012-3231  0.69
2011 Liu Y, Zhang W, Cao Y, Bergmeier S, Akbar H, Colvin R, Qian Y, Ding J, Chen X. Abstract 4068: A novel antiglycolytic small compound inhibits cancer growth in vitro and in vivo by inhibiting glut1 Cancer Research. 71: 4068-4068. DOI: 10.1158/1538-7445.Am2011-4068  0.684
2010 Liu Y, Zhang W, Cao Y, Liu Y, Bergmeier S, Chen X. Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms. Cancer Letters. 298: 176-85. PMID 20678861 DOI: 10.1016/J.Canlet.2010.07.002  0.677
2010 Zhang W, Liu Y, Chen X, Bergmeier SC. Novel inhibitors of basal glucose transport as potential anticancer agents. Bioorganic & Medicinal Chemistry Letters. 20: 2191-4. PMID 20194024 DOI: 10.1016/J.Bmcl.2010.02.027  0.666
Show low-probability matches.